CA2652662C - Methods for the treatment and prevention of ocular disorders - Google Patents

Methods for the treatment and prevention of ocular disorders Download PDF

Info

Publication number
CA2652662C
CA2652662C CA2652662A CA2652662A CA2652662C CA 2652662 C CA2652662 C CA 2652662C CA 2652662 A CA2652662 A CA 2652662A CA 2652662 A CA2652662 A CA 2652662A CA 2652662 C CA2652662 C CA 2652662C
Authority
CA
Canada
Prior art keywords
cyclosporin
compound
certain embodiments
ethoxy
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2652662A
Other languages
English (en)
French (fr)
Other versions
CA2652662A1 (en
Inventor
David Renwick Houck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of CA2652662A1 publication Critical patent/CA2652662A1/en
Application granted granted Critical
Publication of CA2652662C publication Critical patent/CA2652662C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Laser Surgery Devices (AREA)
CA2652662A 2006-05-19 2007-05-18 Methods for the treatment and prevention of ocular disorders Active CA2652662C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80220806P 2006-05-19 2006-05-19
US60/802,208 2006-05-19
PCT/US2007/011919 WO2007136759A2 (en) 2006-05-19 2007-05-18 Method for the treatment and prevention of ocular disorders

Publications (2)

Publication Number Publication Date
CA2652662A1 CA2652662A1 (en) 2007-11-29
CA2652662C true CA2652662C (en) 2015-11-03

Family

ID=37814449

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2652662A Active CA2652662C (en) 2006-05-19 2007-05-18 Methods for the treatment and prevention of ocular disorders

Country Status (12)

Country Link
US (2) US8188052B2 (enExample)
EP (1) EP2023918B1 (enExample)
JP (1) JP5377293B2 (enExample)
CN (1) CN101511357B (enExample)
AT (1) ATE502633T1 (enExample)
AU (1) AU2007254148B2 (enExample)
CA (1) CA2652662C (enExample)
DE (1) DE602007013391D1 (enExample)
DK (1) DK2023918T3 (enExample)
ES (1) ES2361635T3 (enExample)
WO (1) WO2007136759A2 (enExample)
ZA (1) ZA200810113B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
WO2007041632A2 (en) 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
WO2007041631A1 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CN102869367A (zh) * 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
AU2011316690C1 (en) 2010-10-12 2017-01-19 Allergan, Inc. Cyclosporin analogs
EP2627663B1 (en) * 2010-10-12 2018-02-21 Allergan, Inc. Cyclosporin analogs
US9610245B2 (en) * 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
US10429712B2 (en) 2012-04-20 2019-10-01 View, Inc. Angled bus bar
WO2013181339A2 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
RU2019101249A (ru) 2013-06-18 2019-03-05 Вью, Инк. Электрохромные устройства непрямоугольных форм
CN107430118A (zh) * 2013-06-27 2017-12-01 广东盛泽康华生物医药有限公司 对自身免疫状况的分类与管理的方法与仪器
WO2015068020A2 (en) 2013-11-05 2015-05-14 García-Sánchez Gustavo A Immunosuppressive treatments, formulations and methods
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
AU2016373364B2 (en) * 2015-12-14 2019-07-11 Tsung-Chuan Ho Short synthetic peptide and uses thereof
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
US20200366476A1 (en) * 2019-05-17 2020-11-19 Panasonic Avionics Corporation Transient key negotiation for passenger accessible peripherals
CN116870135A (zh) * 2019-10-12 2023-10-13 睿诺医疗科技（上海）有限公司 肾毒素诱发的肾损伤的治疗和预防
CN111920940B (zh) * 2020-09-16 2022-04-05 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
CA3172535A1 (en) * 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
US11564909B2 (en) * 2020-11-30 2023-01-31 Romeg Therapeutics Llc Methods and compositions for oral pilocarpine liquid
EP4201398A1 (en) * 2021-12-24 2023-06-28 Isoxa S.r.l. Isocyclosporin a for topical treatment of ocular diseases
WO2024245384A1 (en) * 2023-06-02 2024-12-05 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
EP0692487A1 (en) 1993-03-31 1996-01-17 Tokyo Tanabe Company Limited Cholestasis ameliorant
EP0773029A4 (en) 1993-07-19 1997-09-03 Tokyo Tanabe Co HEPATITIS C VIRUS PROLIFERATION INHIBITOR
CN1141317C (zh) 1995-07-17 2004-03-10 碳化学公司 有抗人体免疫缺损病毒作用的环孢菌素衍生物
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
ATE254630T1 (de) 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
PT1091975E (pt) 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6521595B1 (en) 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
CZ20013424A3 (cs) 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
US20050009877A1 (en) 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
CN1984670A (zh) 2004-07-13 2007-06-20 诺瓦提斯公司 治疗阿尔茨海默病的环孢菌素
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
PT1802650E (pt) 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
ATE490778T1 (de) 2004-10-01 2010-12-15 Debiopharm Sa Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
NZ555142A (en) 2004-12-23 2010-03-26 Novartis Ag Compounds for flaviviridae treatment
WO2007041632A2 (en) 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US20090306033A1 (en) 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
CN102271688A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv的环孢菌素衍生物和核苷的组合
KR20110116136A (ko) 2009-01-07 2011-10-25 싸이넥시스, 인크. Ｈｃｖ 및 ｈｉｖ 감염의 치료에 사용하기 위한 사이클로스포린 유도체
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽

Also Published As

Publication number Publication date
WO2007136759A3 (en) 2009-04-16
CN101511357A (zh) 2009-08-19
WO2007136759A2 (en) 2007-11-29
CN101511357B (zh) 2011-11-02
EP2023918B1 (en) 2011-03-23
DK2023918T3 (da) 2011-04-26
US20100062975A1 (en) 2010-03-11
US8188052B2 (en) 2012-05-29
ES2361635T3 (es) 2011-06-20
JP5377293B2 (ja) 2013-12-25
JP2009537550A (ja) 2009-10-29
US8551952B2 (en) 2013-10-08
US20120270804A1 (en) 2012-10-25
ATE502633T1 (de) 2011-04-15
AU2007254148A1 (en) 2007-11-29
ZA200810113B (en) 2010-02-24
EP2023918A2 (en) 2009-02-18
CA2652662A1 (en) 2007-11-29
AU2007254148B2 (en) 2013-02-07
DE602007013391D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
AU2007254148B2 (en) Method for the treatment and prevention of ocular disorders
RU2399628C2 (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
EP2163548B1 (en) Prophylactic or therapeutic agent for age-related macular degeneration
EP2614838B1 (en) Diquafosol and hyaluronic acid or salts thereof for the treatment of dry eye
KR101154175B1 (ko) 각결막 장해 치료제
US7196161B2 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
SK230792A3 (en) Agent for healing of eye inflammations
US20250367207A1 (en) Ocular pharmaceutical compositions
JP5517454B2 (ja) Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
AU2009268549A1 (en) Cyclosporin derivatives for treating ocular and dermal diseases and conditions
CA2608457C (en) Ebselen as a prophylactic or therapeutic agent for corneal or conjunctival disorders
CN102834409A (zh) 环孢菌素类似物
JP6509244B2 (ja) 水晶体硬化抑制剤
EP4045032A1 (en) Thiophene derivatives for use in treating portal inflammation and fibrosis
US20170014487A1 (en) Method for treating ocular inflammation
EP1958949A1 (en) Therapeutic agent for corneal/conjuctival disease
JP5087233B2 (ja) 角結膜障害の予防または治療剤
WO2022249942A1 (ja) 網膜の神経細胞の保護剤
CN102905708A (zh) 用于治疗葡萄膜炎的a3ar激动剂
HK1184686B (en) Diquafosol and hyaluronic acid or salts thereof for the treatment of dry eye

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250508

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250508